Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2025-3431

Published: 2025

Journal Articles

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Rong Wang, Jessica Stempel, Rory Shallis, Jan Philipp Bewersdorf, Lourdes Mendez, Maximilian Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2025-6393

Published: 2025

Journal Articles

Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States

Jessica Stempel, Rong Wang, Rory Shallis, Lourdes Mendez, Jan Philipp Bewersdorf, Maximilian Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 6392.

https://doi.org/10.1182/blood-2025-6392

Published: 2025

Journal Articles

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Maximilian Stahl, Jan Philipp Bewersdorf, Rahul Vedula, Yiwen Liu, H. Moses Murdock, Harrison Tsai, Evan Chen, Benjamin Rolles, Nikolai Podoltsev, Lourdes Mendez, Luca Lanino, Alain Mina, Luis E. Aguirre, Mikkael Sekeres, Lionel Ades, R. Coleman Lindsley, Amer Zeidan

Blood (2025) 146 (Supplement 1): 5651.

https://doi.org/10.1182/blood-2025-5651

Published: 2025

Journal Articles

Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

Konan Beke, Abdulrahman Alhajahjeh, Alyssa Grimshaw, Nikolai Podoltsev, Lourdes Mendez, Maximilian Stahl, Amer Zeidan, Jan Philipp Bewersdorf

Blood (2025) 146 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2025-5154

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 3859.

https://doi.org/10.1182/blood-2025-3859

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Blood (2025) 146 (Supplement 1): 874.

https://doi.org/10.1182/blood-2025-874

Published: 2025

Journal Articles

Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.

Daniil Katkov, Lourdes Mendez, Nikolai Podoltsev, Max Stahl, Amer Zeidan, Jan Philipp Bewersdorf

Blood (2025) 146 (Supplement 1): 7322.

https://doi.org/10.1182/blood-2025-7322

Published: 2025

Journal Articles

Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis

Aram Bidikian, Amer Al-Musa, Cameron Hunter, Lourdes Mendez, Nikolai Podoltsev, Maximilian Stahl, Amer Zeidan, Rory Shallis, Jan Philipp Bewersdorf

Blood (2025) 146 (Supplement 1): 5160.

https://doi.org/10.1182/blood-2025-5160

Published: 2025

Journal Articles

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Blood (2025) 146 (Supplement 1): 1086.

https://doi.org/10.1182/blood-2025-1086

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Cameron Hunter, Karthik Chetlapalli, Satoko Ito, Jan Philipp Bewersdorf, Prajwal Boddu, Sabrina Browning, Stephanie Halene, Terri Parker, Scott Huntington, Shalin Kothari, Lourdes Mendez, Natalia Neparidze, Tarsheen Sethi, Maximilian Stahl, Nikolai Podoltsev, Amer Zeidan, Rory Shallis, George Goshua

Blood (2025) 146 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2025-6208

Published: 2025

Journal Articles

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Jan Philipp Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Giuliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Ross Levine, Prithviraj Bose, Raajit Rampal

Blood (2025) 146 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2025-3814

Published: 2025

Journal Articles

Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports

Blood (2025) 146 (Supplement 1): 2555.

https://doi.org/10.1182/blood-2025-2555

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era

Jan Philipp Bewersdorf, Rong Wang, Lourdes Mendez, Max Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 721.

https://doi.org/10.1182/blood-2025-721

Published: 2025

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.

Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): Real-world outcomes in the new AML treatment era

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only